Ruminant Vaccines Market Size To Reach $5.5 Billion By 2030

Ruminant Vaccines Market Growth & Trends

The global ruminant vaccines market size is expected to reach USD 5.5 billion by 2030, registering a CAGR of 6.95% over the forecast period, according to a new report by Grand View Research, Inc. The market is driven by the increasing demand for animal protein, the prevalence of infectious diseases in ruminants, the rising livestock trade, and R&D advancements. In December 2022, Virbac, a key market player, expanded its capabilities with the inauguration of a new R&D center in Taiwan, in response to the growing demand for veterinary vaccines. This has enabled the company to develop innovative solutions and immune stimulants and/or enhance existing products on a domestic, regional, and global level.

The COVID-19 pandemic notably impacted the market for ruminant vaccines. This included disruptions in the supply chain, reduced access to veterinary services, impact on trade and exports, and economic constraints on farmers. For example, in 2020, Indian Immunologicals Ltd reported decreased trade, exports, and institutional businesses due to the pandemic. Despite this, the company continued to be the largest supplier of FMD vaccines in India. Furthermore, the economic slowdown of 2022 also significantly affected the market. Merck & Co., Inc. for instance, reported that livestock product sales were practically flat in 2022. This was attributed to the unfavorable impact of foreign exchange.

Support from governments, regulatory authorities, and animal health organizations drives the adoption of ruminant vaccines. All these institutions worldwide have recognized the importance of preventing and controlling animal diseases. They have implemented various initiatives and regulations to promote the use of vaccines in the ruminant sector. These initiatives include awareness campaigns, vaccination programs, and subsidies or incentives for farmers to vaccinate their animals. For instance, the World Organization for Animal Health manages vaccine banks to ensure the procurement of high-quality vaccines, facilitate economies of scale, and contribute to harmonizing global and regional control programs. As of January 2023, the organization manages 2 active vaccine banks focusing on peste des petits ruminants (PPR) and rabies.

 Request a free sample copy or view report summary: Ruminant Vaccines Market Report

Ruminant Vaccines Market Report Highlights

• The cattle segment dominated the market, based on animal type, in 2022. The sheep & goats segment is projected to expand at the highest CAGR of 9.12% over the projection period

• By vaccine type, the modified/ attenuated live vaccines segment contributed to the largest share of over 52% in 2022. The other vaccines segment, on the other hand, is anticipated to grow the fastest at a rate of 9.4% in the coming years

• In 2022, based on indication, Bovine Respiratory Diseases (BRD) accounted for the highest share of around 35% of the market. The other indications segment is expected to grow at the fastest rate of over 9% during the forecast period

• In terms of route of administration, the injectable segment held the largest share of around 95.0% of the market in 2022, while the intranasal segment is estimated to grow at the highest rate of over 10% during the forecast period from 2023 to 2030

• In 2022, North America accounted for the highest regional share of more than 38.0% of the market. Asia Pacific is anticipated to advance at a growth rate of about 9.0% owing to the thriving dairy and beef sector in key markets of the region

• International trade of livestock and animal products has been increasing due to globalization and changing dietary preferences. However, the movement of animals across borders can also facilitate the spread of infectious diseases. To mitigate this risk, countries and trade organizations enforce strict import and export regulations, including vaccination requirements, driving the demand for ruminant vaccines to ensure compliance with trade regulations

Ruminant Vaccines Market Segmentation

Grand View Research has segmented the global ruminant vaccines market on the basis of animal type, vaccine type, indication, route of administration, and region:

Ruminant Vaccines Animal Type Outlook (Revenue, USD Million, 2018 - 2030)

• Cattle

• Sheep & Goats

Ruminant Vaccines Type Outlook (Revenue, USD Million, 2018 - 2030)

• Modified/ Attenuated Live

• Inactivated (Killed)

• Other Vaccines

Ruminant Vaccines Indication Outlook (Revenue, USD Million, 2018 - 2030)

• BVD Infection

• Bovine Respiratory Diseases (BRD)

• Leptospirosis

• Clostridial diseases

• Diarrhea/ Scours

• FMD

• Other Indications

Ruminant Vaccines Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Injectable

• Intranasal

Ruminant Vaccines Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Netherlands

  • Rest of Europe

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Rest of Asia Pacific

• Latin America

  • Brazil

  • Mexico

  • Argentina

  • Rest of Latin America

• Middle East & Africa

  • South Africa

  • Rest of MEA

List of Key Players in the Ruminant Vaccines Market

• Boehringer Ingelheim International GmbH

• Zoetis Services LLC

• Vaxxinova International BV

• Merck & Co., Inc.

• Bimeda Animal Health Ltd. 

• Indian Immunologicals Ltd.

• Elanco

• Virbac

• Ceva Santé Animale

• CZ Vaccines S.A.U. (Zendal Group)